ARS Pharmaceuticals (SPRY) Competitors $13.50 -1.37 (-9.21%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$13.54 +0.04 (+0.26%) As of 08/22/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY vs. RYTM, RNA, NUVL, AXSM, CRSP, MRUS, ABVX, VKTX, TGTX, and ACADShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Merus (MRUS), Abivax (ABVX), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Its Competitors Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics Merus Abivax Viking Therapeutics TG Therapeutics ACADIA Pharmaceuticals ARS Pharmaceuticals (NASDAQ:SPRY) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Do insiders & institutionals hold more shares of SPRY or RYTM? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is SPRY or RYTM more profitable? ARS Pharmaceuticals has a net margin of -42.74% compared to Rhythm Pharmaceuticals' net margin of -117.13%. ARS Pharmaceuticals' return on equity of -21.85% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-42.74% -21.85% -15.88% Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33% Do analysts recommend SPRY or RYTM? ARS Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 129.63%. Rhythm Pharmaceuticals has a consensus target price of $101.57, suggesting a potential downside of 1.64%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Does the media prefer SPRY or RYTM? In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 21 mentions for ARS Pharmaceuticals and 14 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat ARS Pharmaceuticals' score of -0.25 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SPRY or RYTM? ARS Pharmaceuticals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Which has better valuation & earnings, SPRY or RYTM? ARS Pharmaceuticals has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M14.97$8M-$0.49-27.55Rhythm Pharmaceuticals$130.13M52.71-$260.60M-$3.01-34.31 SummaryARS Pharmaceuticals beats Rhythm Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.47B$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-27.5522.6131.1026.05Price / Sales14.97543.08435.79105.95Price / Cash1,755.96180.4637.7358.48Price / Book6.925.939.536.61Net Income$8M$31.83M$3.26B$265.56M7 Day Performance-7.09%1.89%2.09%1.97%1 Month Performance-25.00%1.33%2.81%-0.36%1 Year Performance4.17%8.84%30.56%19.03% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals2.487 of 5 stars$13.50-9.2%$31.00+129.6%+5.4%$1.47B$89.15M-27.5590Insider TradeRYTMRhythm Pharmaceuticals3.8397 of 5 stars$94.31+2.5%$101.57+7.7%+133.7%$6.26B$130.13M-31.33140News CoveragePositive NewsRNAAvidity Biosciences3.2033 of 5 stars$45.75-1.2%$67.00+46.4%+8.2%$5.51B$8.93M-15.25190Positive NewsInsider TradeOptions VolumeNUVLNuvalent3.2832 of 5 stars$74.95+1.1%$119.60+59.6%-8.3%$5.38BN/A-15.3040News CoverageAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.7967 of 5 stars$103.96-0.8%$178.00+71.2%+36.0%$5.19B$385.69M-20.50380News CoveragePositive NewsCRSPCRISPR Therapeutics3.809 of 5 stars$55.41+0.7%$71.60+29.2%+14.4%$5.04B$37.31M-10.20460MRUSMerus2.3245 of 5 stars$64.60+0.9%$88.50+37.0%+26.5%$4.89B$36.13M-11.7537News CoveragePositive NewsABVXAbivax2.9381 of 5 stars$69.00-1.6%$92.33+33.8%+562.8%$4.38BN/A0.0061Positive NewsShort Interest ↑VKTXViking Therapeutics4.0071 of 5 stars$38.20+0.8%$86.92+127.6%-59.6%$4.29BN/A-24.9620Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3525 of 5 stars$26.39-1.2%$46.25+75.3%+20.7%$4.19B$329M71.32290Positive NewsACADACADIA Pharmaceuticals3.961 of 5 stars$24.82+0.9%$28.88+16.3%+64.2%$4.19B$957.80M18.66510Insider Trade Related Companies and Tools Related Companies RYTM Competitors RNA Competitors NUVL Competitors AXSM Competitors CRSP Competitors MRUS Competitors ABVX Competitors VKTX Competitors TGTX Competitors ACAD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRY) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access